Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs

@article{Hassanein2003AlbuminDI,
  title={Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs},
  author={Tarek I. Hassanein and Deanna L. Oliver and Jan Stange and Christian Luzius Steiner},
  journal={Liver International},
  year={2003},
  volume={23}
}
Abstract Albumin dialysis using the Molecular Adsorbents Recirculating System (MARS) has been found to be beneficial in the treatment of cirrhotic patients with acute decompensation to improve survival as well as reduce associated complications. The present study attempts to analyze the costs involved, and compare it to the benefit as a result of the MARS therapy, thus evaluating its cost‐effectiveness. Using the results of a study by Kim et al. (Hepatology 2001) describing the effects of… 
Albumin dialysis with molecular adsorbent recirculating system (MARS) for the treatment of hepatic encephalopathy in liver failure.
TLDR
The following manuscript reviews the technical features of MARS operation and some of the clinical trials that analyze the efficacy of the system in the therapy of liver diseases.
Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure.
TLDR
In surviving ALF patients, the health-related quality of life after treatment was generally high and comparable to the age- and gender-matched general Finnish population.
MARS dialysis in decompensated alcoholic liver disease: A single‐center experience
TLDR
Although MARS improved laboratory parameters of hepatic detoxification and renal function in patients with acutely decompensated ALD, the patients' mortality remained unsatisfactorily high and the experience does not support the indiscriminative use of MARS in acutely decompensation of chronically stable alcoholic liver disease without further controlled studies.
Survival predictors in patients treated with a molecular adsorbent recirculating system.
TLDR
MARS treatment appears to be ineffective in AOCLF with end-stage cirrhosis without an LTX option, and the etiology of liver disease was the most important prognostic factor.
The molecular adsorbent recirculating system in posthepatectomy liver failure: Results from a prospective phase I study
TLDR
The use of MARS in PHLF is feasible and safe and improves liver function in patients with PHLf, and the 60‐ and 90‐day mortality rates were unexpectedly low compared to a historical control group.
Kosten der stationären Versorgung von Patienten mit akuter Dekompensation einer chronischen Lebererkrankung unter Verwendung des artifiziellen Leberunterstützungssystems MARS
TLDR
The cost for inpatient care of ACLF-patients varies significantly due to the use of technical procedures such as artificial liver support systems, as well as clinical parameter, which is currently not sufficiently reflected in the calculation of public payers’ package reimbursement rates.
Albumin dialysis with mars in post-hepatectomy liver failure (PHLF): experiences from two HPB centers
TLDR
Experiences from Two HPB Centers Albumin Dialysis with Mars in Post-Hepatectomy Liver Failure (PHLF): Experiences from two HPB centers are presented.
Single Pass Albumin Dialysis—A Dose‐Finding Study to Define Optimal Albumin Concentration and Dialysate Flow
TLDR
This study confirmed that SPAD is effective in eliminating albumin-bound as well as water-soluble toxins using a simulation of ALF and evaluated the most effective combination of albumin concentration and dialysate flow in SPAD for the first time.
Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey
TLDR
The superior efficacy of IHD for enhanced elimination, added to its lower cost and wider availability, strengthens its preference as the ECTR of choice in most cases of acute poisoning.
Artificial liver support systems.
  • J. George
  • Medicine
    The Journal of the Association of Physicians of India
  • 2004
TLDR
The various methods of extracorporeal liver support that are available at present are assessed and those that appear to be promising are described.
...
1
2
...

References

SHOWING 1-10 OF 30 REFERENCES
Improvement of hepatorenal syndrome with extracorporeal albumin dialysis mars: Results of a prospective, randomized, controlled clinical trial
  • S. Mitzner, J. Stange, +14 authors R. Schmidt
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2000
TLDR
It is concluded that the removal of albumin‐bound substances with the MARS method can contribute to the treatment of type I HRS.
Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study
TLDR
ECAD appears to be effective and safe for the short‐term treatment of patients with cirrhosis and superimposed acute injury associated with progressive hyperbilirubinemia and may be useful for increasing survival in such patients awaiting liver transplantation.
Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure.
TLDR
It is concluded that the molecular adsorbent recirculating system can contribute to the treatment of critically ill patients with liver failure and different underlying diseases.
Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis.
TLDR
MARS resulted in improved liver biochemistry, cardiovascular haemodynamics, renal function and encephalopathy in patients with severe AH, with an apparent reduction in mortality, and a multi-centre, randomized clinical trial is initiated.
Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system.
  • S. Mitzner, S. Klammt, +4 authors R. Schmidt
  • Medicine
    Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis
  • 2001
TLDR
It is concluded that MARS can improve multiple organ functions in patients with HRS and one man underwent successful liver transplantation 18 months after the treatment.
Review article: the Molecular Adsorbents Recirculating System (MARS) in liver failure
TLDR
Although the clinical experience with MARS is scarce, some pilot studies have reported its effectiveness at improving liver function and hepatic encephalopathy in patients with acute decompensation of chronic liver disease, and renal function in patientswith hepatorenal syndrome type I.
MARS (Molecular Adsorbent Recirculating System): experience in 34 cases of acute liver failure.
As reported in the literature, the mortality rates for patients with Acute Hepatic Failure (AHF) approaches 80% in cases in which liver transplantation is not possible. Post-transplant mortality
Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure
TLDR
Applying MARS treatments to patients with acute exacerbation of chronic liver disease can detoxify blood, improve cerebral circulation, and reduce brain edema, as reflected by the reduction in intracranial pressure and jugular bulb oxygen saturation values in the authors' patients.
Liver support by extracorporeal blood purification: A clinical observation
  • J. Stange, S. Mitzner, +12 authors U. Hopt
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2000
TLDR
It is concluded that in acute excretory failure caused by a chronic liver disease, this treatment provides a therapy option to remove toxins involved in multiorgan dysfunction secondary to liver failure.
A model to predict survival in patients with end‐stage liver disease
TLDR
The MELD scale is a reliable measure of mortality risk in patients with end‐stage liver disease and suitable for use as a disease severity index to determine organ allocation priorities in patient groups with a broader range of disease severity and etiology.
...
1
2
3
...